Netherlands' AgriTech Crown Slips as Report Reveals $18B Opportunity

Jan de Vries · 2026-10-30

The Netherlands has built a reputation as Europe's agricultural powerhouse. But a new report from Invest-NL, the Dutch national investment institution, suggests that crown might be slipping. ### The Warning: A $18 Billion Opportunity at Risk According to the report, *Deep Dive Agrifood Biotech*, the Netherlands could unlock an extra $18 billion (€17 billion) in annual revenue by 2040 if it tackles the barriers holding back its agrifood biotech companies. Without coordinated action on regulation, financing, and commercialization, much of that opportunity will be captured elsewhere. The study draws on interviews with over 150 entrepreneurs, investors, researchers, and policymakers, plus investment data from 2010 to April 2026. It focuses on three areas: seed breeding and genetics, biological agricultural inputs, and biotech-derived food ingredients. ### A Strong Start, But a Weaker Finish The Netherlands boasts world-class research institutions, established seed breeders, and a sophisticated food production ecosystem. Yet scientific excellence isn't translating into globally competitive businesses. The numbers tell the story: the Netherlands accounts for 3.3% of BioTech startups worldwide but only 1.3% of scale-ups, according to data from TNO. In other words, the country is great at generating innovation but struggles to help young companies reach meaningful commercial scale. Invest-NL identifies three recurring weaknesses: - Too few promising technologies become scalable ventures. - Regulatory and validation processes delay market entry. - Insufficient financing prevents companies from reaching industrial production. The stakes are high. In a favorable scenario, Invest-NL estimates annual Dutch agrifood BioTech revenues could hit $27 billion (€25 billion) by 2040, compared with just $8.6–9.7 billion (€8–9 billion) if current conditions persist. Crucially, the report argues that the Netherlands doesn't need to manufacture everything domestically. Instead, it should focus on retaining strategically valuable knowledge, intellectual property, companies, and specialized capabilities, while tapping into European production networks where appropriate. ### Ten Years to Say Yes One of the most striking obstacles is in biological crop protection, where Dutch companies are developing alternatives to conventional chemical pesticides. Getting European regulatory approval for a new biological crop protection product can take eight to ten years. Existing frameworks were largely designed around chemical products, making them a poor fit for certain biological innovations. As a result, some companies prioritize launching in markets like Brazil and the United States, where commercialization moves faster. Invest-NL warns that Europe risks losing ground in a biological crop protection market that could expand seven- to tenfold by 2040. Food biotechnology faces similar hurdles. Regulatory approval for novel ingredients can take one to three years longer in Europe than in the United States, while building a first commercial production facility can require tens or even hundreds of millions of dollars. For fermentation-derived food ingredients alone, Invest-NL estimates that favorable conditions could support about $8.6 billion (€8 billion) in annual Dutch revenues by 2040, compared with around $2.2 billion (€2 billion) under existing policies. The report stresses that faster approvals shouldn't come at the expense of safety. Instead, regulators should offer earlier guidance, more predictable assessments, and opportunities for companies to validate products under real-world conditions. ### The Takeaway Innovation isn't the issue. The Netherlands has plenty of that. The challenge is turning that innovation into commercial success. As Invest-NL's report makes clear, the window to act is now. If the country can streamline regulation, improve access to financing, and support scale-ups, it could secure its position as a global leader in agrifood biotech. If not, others will happily take the crown.